News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kedrion S.p.A. and ProMetic Life Sciences Inc. (PFSCF.PK) Form Strategic Alliance to Develop Orphan Drugs from Plasma



3/13/2007 1:53:35 PM

LUCCA, ITALY, ANNAPOLIS, MD and MONTREAL -- (MARKET WIRE) -- March 13, 2007 -- Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic's proprietary manufacturing process, the Plasma Protein Purification System (PPPS).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES